A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia

Micro-Abstract A phase I study of targeted, dose-escalated busulfan in combination with etoposide as myeloablative therapy for autologous hematopoietic stem cell transplantation in acute myeloid leukemia identified a busulfan area under the curve (AUC) target of 1400 μmol/min as the maximum clinical...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2015-06, Vol.15 (6), p.377-383
Hauptverfasser:	Mannis, Gabriel N, Andreadis, Charalambos, Logan, Aaron C, Damon, Lloyd E, Benet, Leslie Z, Ai, Weiyun Z, Gaensler, Karin M.L, Kaplan, Lawrence D, Koplowicz, Yelena B, Linker, Charles A, Olin, Rebecca L, Sayre, Peter H, Smith, Catherine C, Sudhindra, Akshay, Venstrom, Jeffrey M, Wolf, Jeffrey L, Martin, Thomas G
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Myelogenous Leukemia Administration, Intravesical Adult Area Under Curve Autologous transplant Busulfan - administration & dosage Busulfan - adverse effects Busulfan - pharmacokinetics Disease-Free Survival Etoposide - administration & dosage Hematology, Oncology and Palliative Medicine Hematopoietic Stem Cell Transplantation High-dose chemotherapy Humans Leukemia, Myeloid, Acute - therapy Maximum Tolerated Dose Middle Aged Mucositis - chemically induced Myeloablative Agonists - administration & dosage Myeloablative Agonists - adverse effects Myeloablative Agonists - pharmacokinetics Pharmacokinetics Phase I Clinical Trial Recurrence Transplantation Conditioning - methods Transplantation, Autologous Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!